Journal
MEDICINA CLINICA
Volume 148, Issue 9, Pages 394-400Publisher
ELSEVIER ESPANA SLU
DOI: 10.1016/j.medcli.2016.11.026
Keywords
Antiphospholipid syndrome; Thrombocytopenia; Antiphospholipid antibodies
Categories
Ask authors/readers for more resources
Introduction: The antiphospholipid syndrome (APS) is an acquired immune disorder defined by the presence of thrombosis (arterial and/or venous) and/or pregnancy morbidity along with the presence of positive antiphospholipid antibodies (aPL). There is a clear relationship between aPL and some events not included in the clinical criteria, including haematologic. Objectives: a) to study the probability of developing clinical APS in patients with positive aPL and thrombopenia; b) to identify potential risk factors for thrombosis, and c) to study the association between thrombocytopenia and aPL. Methods: A retrospective study of 138 patients with positive aPL without fulfilling clinical criteria for APS. Thrombocytopenia was defined as a platelet count <= 100,000/mu l. Patients with other causes of thrombocytopenia were excluded. Results: Seventeen of the 138 (12%) patients in the study had thrombocytopenia. The mean platelet count was 60,000/mu l. The risk of developing thrombocytopenia was higher in smokers (OR 2.8; P = .044), in those with lupus anticoagulant (OR 13.5; P < .001) and those with higher burden of aPL (OR 50.8; P < .001). After a mean follow-up of 146 +/- 60.3 months, 5 patients with thrombocytopenia (29.4%) developed thrombosis. Conclusions: In our series, the incidence of thrombocytopenia is 12%. aPL-positive patients who develop thrombocytopenia have a potential risk of developing thrombosis. Tobacco could be a risk factor for thrombocytopenia. Autoantibodies load is a risk factor for the development of thrombocytopenia. (C) 2016 Elsevier Espana, S.L.U. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available